阿立哌唑与利培酮治疗精神分裂症患者的疗效及不良反应

Efficacy and adverse reactions of Aripiprazole and Risperidone in treatment of patients with schizophrenia

目的:观察阿立哌唑、利培酮治疗精神分裂症患者的疗效、不良反应及安全性。方法:将60例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予患者阿立哌唑、利培酮治疗8周,于治疗前以及治疗2、4和8周采用阳性与阴性症状量表(PANSS)评定患者的疗效,不良反应量表(TESS)评定患者的不良反应。结果:两组患者治疗的疗效相当。利培酮组患者的锥体外系反应、内分泌以及体重增加多于阿立哌唑组。结论:阿立哌唑治疗精神分裂症患者的疗效与利培酮相似,但不良反应更少。

Objective： To observe efficacy, adverse reactions and safety of Aripiprazole and Risperidone in treatment of pa-tients with schizophrenia. Methods： 60 cases meeting CCMD3 diagnostic criteria for schizophrenia were randomly divided into 2 groups. They were treated with Aripiprazole and Risperidone for 8 weeks, respectively. Before and 2, 4 and 8 weeks after the treat-ment, PANSS （positive and negative symptom scale） and TESS （treatment emergent symptom scale） were used to evaluate the efficacy and adverse reactions. Results：The two groups had a similar efficacy;however, the extrapyramidal system reactions, endocrine, and weight gain in Risperidone group were more than those of Aripiprazole group. Conclusions：Aripiprazole in the treatment of the patients with schizophrenia has a similar efficacy with Risperidone, but has fewer adverse reactions.